162 related articles for article (PubMed ID: 37058173)
21. Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin's lymphoma patients treated with chemotherapy.
Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
Value Health; 2011; 14(2):253-62. PubMed ID: 21402294
[TBL] [Abstract][Full Text] [Related]
22. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
23. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
Main C; Pitt M; Moxham T; Stein K
Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
[TBL] [Abstract][Full Text] [Related]
24. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
Guzauskas GF; Masaquel A; Reyes C; Bernaards C; Krivasi T; Veenstra DL
J Med Econ; 2018 Oct; 21(10):960-967. PubMed ID: 29898619
[TBL] [Abstract][Full Text] [Related]
26. Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up.
Soini EJO; Martikainen JA; Nousiainen T
Ann Oncol; 2011 May; 22(5):1189-1197. PubMed ID: 21135053
[TBL] [Abstract][Full Text] [Related]
27. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
Coiffier B
Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
[TBL] [Abstract][Full Text] [Related]
28. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma.
van Keep M; Gairy K; Seshagiri D; Thilakarathne P; Lee D
BMC Cancer; 2016 Aug; 16(1):598. PubMed ID: 27488675
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
Lyman G; Lalla A; Barron R; Dubois RW
Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
[TBL] [Abstract][Full Text] [Related]
32. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
33. Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study.
Dourthe ME; Phulpin A; Auperin A; Bosq J; Couec ML; Dartigues P; Ducassou S; Garnier N; Haouy S; Leblanc T; Leruste A; Paillard C; Rigaud C; Simonin M; Patte C; Minard-Colin V
Haematologica; 2022 Sep; 107(9):2173-2182. PubMed ID: 35236054
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy].
Malliti M; Junot H; Fievet MH; Gabarre J; Taright N; Vernant JP; Thuillier A
Ann Med Interne (Paris); 2003 May; 154(3):139-47. PubMed ID: 12910040
[TBL] [Abstract][Full Text] [Related]
35. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
36. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study.
Rigaud C; Auperin A; Jourdain A; Haouy S; Couec ML; Aladjidi N; Gandemer V; Lambliotte A; Plat G; Landman-Parker J; Michon J; Leblanc T; Patte C; Minard-Colin V
Pediatr Blood Cancer; 2019 Sep; 66(9):e27873. PubMed ID: 31207026
[TBL] [Abstract][Full Text] [Related]
37. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma.
Sparano JA; Lee JY; Kaplan LD; Ramos JC; Ambinder RF; Wachsman W; Aboulafia D; Noy A; Henry DH; Ratner L; Cesarman E; Chadburn A; Mitsuyasu R
Haematologica; 2021 Mar; 106(3):730-735. PubMed ID: 32107337
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma.
Best JH; Hornberger J; Proctor SJ; Omnes LF; Jost F
Value Health; 2005; 8(4):462-70. PubMed ID: 16091023
[TBL] [Abstract][Full Text] [Related]
39. Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis.
Khor S; Beca J; Krahn M; Hodgson D; Lee L; Crump M; Bremner KE; Luo J; Mamdani M; Bell CM; Sawka C; Gavura S; Sullivan T; Trudeau M; Peacock S; Hoch JS
BMC Cancer; 2014 Aug; 14():586. PubMed ID: 25117912
[TBL] [Abstract][Full Text] [Related]
40. The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma.
Muszbek N; Kadambi A; Lanitis T; Hatswell AJ; Patel D; Wang L; Singer JW; Pettengell R
Clin Ther; 2016 Mar; 38(3):503-15. PubMed ID: 26856929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]